Vor Biopharma Stock Performance
| VOR Stock | USD 2.21 0.17 7.14% |
Vor Biopharma holds a performance score of 15 on a scale of zero to a hundred. The entity has a beta of 2.17, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vor Biopharma will likely underperform. Use Vor Biopharma semi variance, as well as the relationship between the rate of daily change and relative strength index , to analyze future returns on Vor Biopharma.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Vor Biopharma are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Vor Biopharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.14) | Five Day Return (11.60) | Year To Date Return 97.32 | Ten Year Return (94.11) | All Time Return (94.11) |
1 | Disposition of 876 shares by Tirtha Chakraborty of Vor Biopharma at 0.56 subject to Rule 16b-3 | 05/06/2025 |
2 | FMR LLCs Strategic Acquisition of Vor Biopharma Inc Shares - GuruFocus | 05/16/2025 |
3 | Acquisition by Namouni Fouad of 30000 shares of Vor Biopharma at 0.1868 subject to Rule 16b-3 | 05/22/2025 |
4 | Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune ... | 06/25/2025 |
5 | PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and 175 Million Private Placement | 06/26/2025 |
6 | Vor Biopharma Stock Rating Baird Raises Price Target VOR Stock News | 06/27/2025 |
7 | Vor Biopharmas 125 Million Investment Paves Way For Multi-Billion Dollar Autoimmune Market | 06/30/2025 |
8 | Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635 | 07/01/2025 |
9 | Vor Biopharma Stock Skyrockets Whats Next - StocksToTrade | 07/07/2025 |
10 | Insider Trading | 07/09/2025 |
11 | Vor Bio Welcomes New CFO Sandy Mahatme VOR Stock News | 07/10/2025 |
12 | Vor Bio Appoints New Chief Development Officer VOR Stock News | 07/17/2025 |
13 | Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635 VOR Stock News | 07/18/2025 |
| Begin Period Cash Flow | 33.8 M | |
| Total Cashflows From Investing Activities | 96.9 M |
Vor Biopharma Relative Risk vs. Return Landscape
If you would invest 69.00 in Vor Biopharma on April 21, 2025 and sell it today you would earn a total of 152.00 from holding Vor Biopharma or generate 220.29% return on investment over 90 days. Vor Biopharma is generating 3.772% of daily returns assuming volatility of 18.897% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than Vor, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Vor Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vor Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vor Biopharma, and traders can use it to determine the average amount a Vor Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1996
| Best Portfolio | Best Equity | VOR | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 18.9 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.77 actual daily | 76 76% of assets have lower returns |
Risk-Adjusted Return
| 0.2 actual daily | 15 85% of assets perform better |
Based on monthly moving average Vor Biopharma is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vor Biopharma by adding it to a well-diversified portfolio.
Vor Biopharma Fundamentals Growth
Vor Stock prices reflect investors' perceptions of the future prospects and financial health of Vor Biopharma, and Vor Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vor Stock performance.
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.55 | ||||
| Current Valuation | 246.91 M | ||||
| Shares Outstanding | 124.96 M | ||||
| Price To Book | 4.18 X | ||||
| EBITDA | (113.39 M) | ||||
| Net Income | (116.91 M) | ||||
| Cash And Equivalents | 151.09 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 31.83 M | ||||
| Debt To Equity | 0.24 % | ||||
| Current Ratio | 12.95 X | ||||
| Book Value Per Share | 0.53 X | ||||
| Cash Flow From Operations | (99.66 M) | ||||
| Earnings Per Share | (1.51) X | ||||
| Market Capitalization | 276.16 M | ||||
| Total Asset | 142.89 M | ||||
| Retained Earnings | (456.99 M) | ||||
| Working Capital | 77.89 M | ||||
About Vor Biopharma Performance
Assessing Vor Biopharma's fundamental ratios provides investors with valuable insights into Vor Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Vor Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.86) | |
| Return On Capital Employed | (0.98) | (1.02) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (1.21) | (1.27) |
Things to note about Vor Biopharma performance evaluation
Checking the ongoing alerts about Vor Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vor Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vor Biopharma is way too risky over 90 days horizon | |
| Vor Biopharma appears to be risky and price may revert if volatility continues | |
| Vor Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Reported Net Loss for the year was (116.91 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (99.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 32.0% of the company outstanding shares are owned by insiders | |
| Latest headline from simplywall.st: C4 Therapeutics, Inc. Surges 27 percent Yet Its Low PS Is No Reason For Excitement |
- Analyzing Vor Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vor Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Vor Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vor Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vor Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vor Biopharma's stock. These opinions can provide insight into Vor Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.